Screening Services for ASO Gene Therapy

Antisense oligonucleotide therapy uses single-stranded oligonucleotides that can alter RNA expression and splicing and thereby reduce, restore, or modify protein expression in personalized ASO gene therapy.

Screening assays are designed to measure the results of distinct mechanisms of action, such as RNaseH recruitment, splicing modification, and miRNA targeting. Thorough ASO profiling ensures efficient binding and effective modulation to predict successful personalized antisense therapy. Our partnership with Fios Genomics enables faster and scalable ASO design for your oligonucleotide project needs, taking into account the well-established designing rules.

How do ASO’s work? MOA chosen is dependent on specific gene mutation

ASO-Induced Gene Knockdown In Vitro Assay

Charles River has developed a miniaturized (384-well format), reverse transcription PCR (RT-qPCR)-based assays to measure antisense oligonucleotide (ASO)-induced gene knockdown or splicing. This assay uses negative (e.g., scrambled or mismatch) and gene-specific positive control antisense oligonucleotides for assay development to identify and profile ASOs with the ability to reduce or restore expression levels of gene(s) of interest (GOI).

Alternating cycles of ASO design and testing of ASO with the use of concentration-response curves, ASO lead selection can be performed for lead selection and prioritization. We employ both human (patient-derived) cell models as well as relevant rodent cell models to allow transition into in vivo pharmacology and safety studies.

Image of a scientist walking down a street.

Every challenge. Every day. Every life.

How was a n of 1 antisense oligonucleotide therapy was developed for just one patient.

Read more


ASO Gene Therapy Experimental Study Design

In the following example, 192 ASOs were tested at 30 nM concentration for their ability to reduce target gene expression in a mouse neuronal cell line. A selection of antisense oligonucleotides was tested in a 6-point CRC (3-fold dilutions).

Format: 96-well plates (ASO transfection) and 384-well plates (RT-qPCR)
ASO delivery: Transfection using RNAiMax, in biological duplicates (two separate wells in a single experimental run)
RNA harvesting: Cells-to C (subscript T) 1-step Taqman® kit, GOI and housekeeping gene (HKG) amplified in singleplex reactions in technical triplicates

ASO screening study schematic


ASO-Induced Gene Knocked Down Assay Quality Control

Three figures showing graphed data from an ASO screening assay.

  • Strong separation of assay signal for positive and negative control antisense oligonucleotides for all plates tested (Figure 1A)
  • No effect of control ASOs on housekeeping gene expression as compared to vehicle-transfected controls (Figure 1B)
  • No marked intra-plate or inter-plate variability was observed between positive and negative control ASOs (Figures 1A-B)

Excellent reproducibility, as evident from the Pearson correlation between relative gene expression of the biological duplicates, Cor=0.94 (Figure 2)


Antisense Oligonucleotide Profiling Screen

Two figures showing graphed data from ASO profiling assays X and Y

Test ASOs X and Y concentration-dependently induced target gene knockdown without affecting housekeeping gene expression

  • Up to ~90% ASO-induced target gene knockdown was obtained
  • Potency of ASO-induced target gene knockdown was ~ 10 nM (plC(subscript50) = ~8.0)

Consult an ASO Screening Specialist

Frequently Asked Questions (FAQs) for Antisense Oligonucleotide Therapy